View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsBlueprint Medicines 将来の成長Future 基準チェック /66Blueprint Medicines利益と収益がそれぞれ年間60.8%と21.1%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に29.3% 61.4%なると予測されています。主要情報60.8%収益成長率61.38%EPS成長率Biotechs 収益成長22.8%収益成長率21.1%将来の株主資本利益率29.27%アナリストカバレッジGood最終更新日07 Jul 2025今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jul 18+ 1 more updateBlueprint Medicines Corporation Announces Directorate and Committee ChangesBlueprint Medicines Corporation (the “Company”), on June 2, 2025, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”), with SANOFI, a French soci é t é anonyme (“Parent”), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (“Aventis”), and Rothko Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Aventis (“Purchaser”). In accordance with the Merger Agreement, at the Effective Time, each of the directors of the Company (Jeffrey W. Albers, Daniella Beckman, Alexis Borisy, Lonnel Coats, Habib Dable, Mark Goldberg, M.D., Kathryn Haviland, Lynn Seely, M.D., and John Tsai, M.D.) resigned from his or her respective position as a member of the Company’s board of directors and any committee thereof. As of the Effective Time, in accordance with the Merger Agreement, Michael J. Tolpa, the sole director of Purchaser immediately prior to the Effective Time, became the sole director of the Company.お知らせ • Jul 17Blueprint Medicines Corporation(NasdaqGS:BPMC) dropped from NASDAQ Biotechnology IndexBlueprint Medicines Corporation has been dropped from the NASDAQ Biotechnology Index.お知らせ • Jun 13Blueprint Medicines Corporation Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT® (avapritinib) Treatment at 2025 EHA and EAACI CongressesBlueprint Medicines Corporation announced data presentations reflecting over a decade of collaboration with clinical experts and patient advocates to transform the treatment of systemic mastocytosis (SM). Key results continue to position AYVAKIT®?/AYVAKYT®? (avapritinib) as the durable standard of care across indolent and advanced SM, and highlight the real-world burden of the disease, reinforcing the importance of treating with a therapy that addresses the root cause of SM. These data will be reported at the 2025 European Hematology Association (EHA2025) Hybrid Congress, being held June 12 to 15 in Milan, Italy, and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, being held June 13 to 16 in Glasgow, United Kingdom. PIONEER Three-Year Data: Durable Clinical Benefits and Consistent Safety Profile with Long-Term AYVAKIT Use in ISM: As previously presented, AYVAKIT demonstrated robust improvements through 144 weeks in overall symptom and symptom domain measures (skin, gastrointestinal, neurocognitive) representative of real-world patient impacts. AYVAKIT showed a well-tolerated safety profile and a low discontinuation rate due to treatment-related adverse events (TRAEs; 3%) with a median of three years of exposure, and some patients out to five years on therapy. Common TRAEs included low-grade edemas, headache and nausea. In newly reported data, AYVAKIT showed sustained clinical benefits across quality-of-life measures that reflect general health status and are broadly recognized by allergists/immunologists, validating previously presented results from the disease-specific, Mastocytosis Quality of Life (MC-QoL) questionnaire. PATHFINDER/EXPLORER Multi-Year Data: Long-Term Survival Benefits of AYVAKIT in Advanced SM: AYVAKIT showed prolonged overall survival (OS) in PATHFINDER and EXPLORER, when indirectly compared to real-world data for midostaurin from the German Registry on Disorders of Eosinophils and Mast Cells (GREM). AYVAKIT led to meaningful survival benefits in patients across all prognostic categories (low, intermediate and high risk), per the Revised Mutation-Adjusted Risk Score (MARS-R) – a new OS risk assessment tool for advanced SM. Conducted in collaboration with University Hospital Mannheim, the analyses validate the MARS-R tool's ability to assess OS risks in advanced SM patients treated with AYVAKIT or midostaurin, using clinical and genetic parameters. The MARS-R was developed to inform physician care decisions based on individual patient needs. PRISM Data: Substantial Disease Burden Across Broad Population of Patients with ISM: PRISM is one of the largest studies characterizing the impact of SM from both patient and clinical perspectives. Across the spectrum of disease severity, patients with ISM experienced physical, social and emotional challenges that caused meaningful disruption to their daily lives. Patients reported a broad constellation of disease-related impacts, including limitations to physical activities, work/college and relationships; problems with pain/discomfort and anxiety/depression; and adjustments in their daily lives to avoid certain foods, extended sun exposure and smells.お知らせ • Jun 02Sanofi (ENXTPA:SAN) agreed to acquire Blueprint Medicines Corporation (NasdaqGS:BPMC) from Sixth Street Partners, LLC for $8.72 billion.Sanofi (ENXTPA:SAN) agreed to acquire Blueprint Medicines Corporation (NasdaqGS:BPMC) from Sixth Street Partners, LLC for $8.72 billion on June 2, 2025. Under the terms of the acquisition, Sanofi will pay $129.00 per share in cash at closing, representing an equity value of approximately $9.1 billion. Blueprint shareholders also will receive one non-tradeable contingent value right (CVR) which will entitle the holder to receive two potential milestone payments of $2 and $4 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808. Sanofi will pay $344.237175 million for 2.549905 million for Restricted stock units. Sanofi will pay $39.868875 million for 0.295325 million for Performance-based restricted stock units. Sanofi will pay $413.578677 million for 6.925296 million options. The total equity value of the transaction, including potential CVR payments, represents approximately $9.5 billion on a fully diluted basis. The consummation of the tender offer is subject to customary closing conditions, including the tender of a number of shares of Blueprint common stock representing at least a majority of the outstanding shares of Blueprint common stock, the receipt of required regulatory approvals, and other customary conditions. Sanofi currently expects to complete the acquisition in the third quarter of 2025. Sanofi plans to finance the transaction with a combination of cash on hand and proceeds from new debt. The tender offer is not subject to any financing condition. It is immediately accretive to gross margin and accretive to business operating income and EPS after 2026. Upon termination of the Merger Agreement, (i) Sanofi under specified circumstances, including termination following a final order, decree or ruling arising in connection with certain antitrust or foreign investment laws, will be required to pay the Blueprint Medicines a termination fee in the amount of $500 million; and (ii) Blueprint Medicines under specified circumstances, including termination by the Blueprint Medicines to accept and enter into an agreement with respect to a superior proposal, will be required to pay Parent a termination fee in the amount of $318 million. The Company Board unanimously (i) determined that the Merger Agreement and the transactions contemplated thereby, including the Offer and the Merger, are advisable and fair to, and in the best interests of, the Company and the holders of the Shares, (ii) adopted the Merger Agreement and approved the execution, delivery and performance by the Company of the Merger Agreement and the consummation of the transactions contemplated thereby, including the Offer and the Merger, and (iii) resolved to recommend that the holders of the Shares accept the Offer and tender their Shares pursuant to the Offer and the transaction is subject to approval of Blueprint Medicines. Michael J. Aiello; Sachin Kohli of Weil, Gotshal & Manges LLP, Paris served as legal advisor to Sanofi, and Stuart M. Cable, Lisa R. Haddad and James Ding of Goodwin Procter LLP served as legal advisor to Blueprint Medicines. Centerview Partners LLC acted as financial advisor to Blueprint Medicines Corporation.業績と収益の成長予測BIT:1BPMC - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20271,1712381943201512/31/202695672721131912/31/2025721-44-65-197193/31/2025562-156-151-146N/A12/31/2024509-67-197-193N/A9/30/2024434-128-251-242N/A6/30/2024363-205-348-333N/A3/31/2024282-288-430-415N/A12/31/2023249-507-453-437N/A9/30/2023216-555-492-479N/A6/30/2023226-554-515-505N/A3/31/2023205-581-503-493N/A12/31/2022204-558-511-502N/A9/30/2022272-718-404-395N/A6/30/2022230-702-367-361N/A3/31/2022221-650-310-306N/A12/31/2021180-644-302-299N/A9/30/2021107-411-312-309N/A6/30/2021828340407409N/A3/31/2021809325369371N/A12/31/2020794314384387N/A9/30/2020811333361367N/A6/30/202075-395-340-327N/A3/31/202072-371-321-307N/A12/31/201967-348-292-278N/A9/30/201916-362-311-301N/A6/30/20198-340-291-284N/A3/31/201944-267-214-206N/A12/31/201845-237N/A-175N/A9/30/201845-205N/A-142N/A6/30/201852-170N/A-114N/A3/31/201817-177N/A-138N/A12/31/201721-148N/A-120N/A9/30/201727-120N/A-104N/A6/30/201726-99N/A-96N/A3/31/201727-85N/A-86N/A12/31/201628-72N/A-25N/A9/30/201625-67N/A-19N/A6/30/201622-63N/A-13N/A3/31/201618-58N/A-6N/A12/31/201511-56N/A-32N/A9/30/20157-57N/A-30N/A6/30/20153-56N/A-26N/A3/31/20151-52N/A-24N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 1BPMCは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 2.8% ) よりも高い成長率であると考えられます。収益対市場: 1BPMC今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。高成長収益: 1BPMC今後 3 年以内に収益を上げることが予想されます。収益対市場: 1BPMCの収益 ( 21.1% ) Italian市場 ( 5.8% ) よりも速いペースで成長すると予測されています。高い収益成長: 1BPMCの収益 ( 21.1% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 1BPMCの 自己資本利益率 は、3年後には高くなると予測されています ( 29.3 %)成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/07/17 15:58終値2025/07/17 00:00収益2025/03/31年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Blueprint Medicines Corporation 19 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。10 アナリスト機関George FarmerBMO Capital Markets Equity ResearchDane LeoneBTIGArlinda LeeCanaccord Genuity7 その他のアナリストを表示
お知らせ • Jul 18+ 1 more updateBlueprint Medicines Corporation Announces Directorate and Committee ChangesBlueprint Medicines Corporation (the “Company”), on June 2, 2025, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”), with SANOFI, a French soci é t é anonyme (“Parent”), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent (“Aventis”), and Rothko Merger Sub Inc., a Delaware corporation and wholly owned subsidiary of Aventis (“Purchaser”). In accordance with the Merger Agreement, at the Effective Time, each of the directors of the Company (Jeffrey W. Albers, Daniella Beckman, Alexis Borisy, Lonnel Coats, Habib Dable, Mark Goldberg, M.D., Kathryn Haviland, Lynn Seely, M.D., and John Tsai, M.D.) resigned from his or her respective position as a member of the Company’s board of directors and any committee thereof. As of the Effective Time, in accordance with the Merger Agreement, Michael J. Tolpa, the sole director of Purchaser immediately prior to the Effective Time, became the sole director of the Company.
お知らせ • Jul 17Blueprint Medicines Corporation(NasdaqGS:BPMC) dropped from NASDAQ Biotechnology IndexBlueprint Medicines Corporation has been dropped from the NASDAQ Biotechnology Index.
お知らせ • Jun 13Blueprint Medicines Corporation Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT® (avapritinib) Treatment at 2025 EHA and EAACI CongressesBlueprint Medicines Corporation announced data presentations reflecting over a decade of collaboration with clinical experts and patient advocates to transform the treatment of systemic mastocytosis (SM). Key results continue to position AYVAKIT®?/AYVAKYT®? (avapritinib) as the durable standard of care across indolent and advanced SM, and highlight the real-world burden of the disease, reinforcing the importance of treating with a therapy that addresses the root cause of SM. These data will be reported at the 2025 European Hematology Association (EHA2025) Hybrid Congress, being held June 12 to 15 in Milan, Italy, and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, being held June 13 to 16 in Glasgow, United Kingdom. PIONEER Three-Year Data: Durable Clinical Benefits and Consistent Safety Profile with Long-Term AYVAKIT Use in ISM: As previously presented, AYVAKIT demonstrated robust improvements through 144 weeks in overall symptom and symptom domain measures (skin, gastrointestinal, neurocognitive) representative of real-world patient impacts. AYVAKIT showed a well-tolerated safety profile and a low discontinuation rate due to treatment-related adverse events (TRAEs; 3%) with a median of three years of exposure, and some patients out to five years on therapy. Common TRAEs included low-grade edemas, headache and nausea. In newly reported data, AYVAKIT showed sustained clinical benefits across quality-of-life measures that reflect general health status and are broadly recognized by allergists/immunologists, validating previously presented results from the disease-specific, Mastocytosis Quality of Life (MC-QoL) questionnaire. PATHFINDER/EXPLORER Multi-Year Data: Long-Term Survival Benefits of AYVAKIT in Advanced SM: AYVAKIT showed prolonged overall survival (OS) in PATHFINDER and EXPLORER, when indirectly compared to real-world data for midostaurin from the German Registry on Disorders of Eosinophils and Mast Cells (GREM). AYVAKIT led to meaningful survival benefits in patients across all prognostic categories (low, intermediate and high risk), per the Revised Mutation-Adjusted Risk Score (MARS-R) – a new OS risk assessment tool for advanced SM. Conducted in collaboration with University Hospital Mannheim, the analyses validate the MARS-R tool's ability to assess OS risks in advanced SM patients treated with AYVAKIT or midostaurin, using clinical and genetic parameters. The MARS-R was developed to inform physician care decisions based on individual patient needs. PRISM Data: Substantial Disease Burden Across Broad Population of Patients with ISM: PRISM is one of the largest studies characterizing the impact of SM from both patient and clinical perspectives. Across the spectrum of disease severity, patients with ISM experienced physical, social and emotional challenges that caused meaningful disruption to their daily lives. Patients reported a broad constellation of disease-related impacts, including limitations to physical activities, work/college and relationships; problems with pain/discomfort and anxiety/depression; and adjustments in their daily lives to avoid certain foods, extended sun exposure and smells.
お知らせ • Jun 02Sanofi (ENXTPA:SAN) agreed to acquire Blueprint Medicines Corporation (NasdaqGS:BPMC) from Sixth Street Partners, LLC for $8.72 billion.Sanofi (ENXTPA:SAN) agreed to acquire Blueprint Medicines Corporation (NasdaqGS:BPMC) from Sixth Street Partners, LLC for $8.72 billion on June 2, 2025. Under the terms of the acquisition, Sanofi will pay $129.00 per share in cash at closing, representing an equity value of approximately $9.1 billion. Blueprint shareholders also will receive one non-tradeable contingent value right (CVR) which will entitle the holder to receive two potential milestone payments of $2 and $4 per CVR for the achievement, respectively, of future development and regulatory milestones for BLU-808. Sanofi will pay $344.237175 million for 2.549905 million for Restricted stock units. Sanofi will pay $39.868875 million for 0.295325 million for Performance-based restricted stock units. Sanofi will pay $413.578677 million for 6.925296 million options. The total equity value of the transaction, including potential CVR payments, represents approximately $9.5 billion on a fully diluted basis. The consummation of the tender offer is subject to customary closing conditions, including the tender of a number of shares of Blueprint common stock representing at least a majority of the outstanding shares of Blueprint common stock, the receipt of required regulatory approvals, and other customary conditions. Sanofi currently expects to complete the acquisition in the third quarter of 2025. Sanofi plans to finance the transaction with a combination of cash on hand and proceeds from new debt. The tender offer is not subject to any financing condition. It is immediately accretive to gross margin and accretive to business operating income and EPS after 2026. Upon termination of the Merger Agreement, (i) Sanofi under specified circumstances, including termination following a final order, decree or ruling arising in connection with certain antitrust or foreign investment laws, will be required to pay the Blueprint Medicines a termination fee in the amount of $500 million; and (ii) Blueprint Medicines under specified circumstances, including termination by the Blueprint Medicines to accept and enter into an agreement with respect to a superior proposal, will be required to pay Parent a termination fee in the amount of $318 million. The Company Board unanimously (i) determined that the Merger Agreement and the transactions contemplated thereby, including the Offer and the Merger, are advisable and fair to, and in the best interests of, the Company and the holders of the Shares, (ii) adopted the Merger Agreement and approved the execution, delivery and performance by the Company of the Merger Agreement and the consummation of the transactions contemplated thereby, including the Offer and the Merger, and (iii) resolved to recommend that the holders of the Shares accept the Offer and tender their Shares pursuant to the Offer and the transaction is subject to approval of Blueprint Medicines. Michael J. Aiello; Sachin Kohli of Weil, Gotshal & Manges LLP, Paris served as legal advisor to Sanofi, and Stuart M. Cable, Lisa R. Haddad and James Ding of Goodwin Procter LLP served as legal advisor to Blueprint Medicines. Centerview Partners LLC acted as financial advisor to Blueprint Medicines Corporation.